A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma

Khaled,Hussein; Azim,Hamdy  Abdel; Barsoum,Emad; Chahine,George; Shamseddine,Ali; Metaal,Gamal  Abdel; Omar,Abbas; Jazeih,Abdul  Rahman; Haggag,Rasha; Badran,Atef

doi:10.3892/mco.2015.603

September-2015 Volume 3 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2015 Volume 3 Issue 5

Full Size Image

Article

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma

Authors:
- Hussein Khaled
- Hamdy Abdel Azim
- Emad Barsoum
- George Chahine
- Ali Shamseddine
- Gamal Abdel Metaal
- Abbas Omar
- Abdul Rahman Jazeih
- Rasha Haggag
- Atef Badran
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo 11796, Egypt, Department of Clinical Oncology, Faculty of Medicine, Cairo University, Cairo 11796, Egypt, Department of Hematology‑Oncology, Hôtel‑Dieu de France Hospital, Beirut 1107 2020, Lebanon , Department of Internal Medicine, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon, Department of Medical Oncology, Maadi Military Hospital, Cairo 11796, Egypt, Department of Clinical Oncology, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt, Department of Oncology, National Guard Hospital, Riyadh 11564, Kingdom of Saudi Arabia, Department of Medical Oncology, Zagazig University, Sharkia 44519, Egypt
Pages: 1099-1102
|
Published online on: July 16, 2015

https://doi.org/10.3892/mco.2015.603
Expand metrics +

Abstract

The treatment of advanced renal cell carcinoma (RCC) has advanced significantly over the last two decades. This multicenter study was designed with the primary objective to evaluate the efficacy and safety of sorafenib as first‑line treatment in patients with advanced or metastatic RCC in the Middle East, who were considered to be ineligible for other approved first‑line therapies. A total of 75 eligible patients from 8 centers in the Middle East were included in this study. The patients comprised 48 men and 27 women, with a median age of 52 years (range, 19‑78 years). A total of 50 patients had clear cell carcinoma, 17 had papillary carcinoma and 8 had other pathological subtypes. At enrollment, 55 of the 75 patients had undergone previous nephrectomy. A total of 67 patients presented with metastatic disease, while 8 patients had regional residual lesions or local recurrence. The patients were treated with 400 mg oral sorafenib twice daily on a continuous basis as a single agent. Treatment was discontinued upon disease progression, prohibitive toxicity, surgical complications, loss to follow‑up, or refusal to continue therapy. The median treatment duration was 21 weeks (range, 1‑137 weeks). Sorafenib was tolerated by the majority of the patients. Grade 3/4 hand‑foot syndrome occurred in 17 patients; diarrhea, elevated liver enzymes and fatigue were observed in 3 patients each; and grade 3̸4 vomiting, hypertension and anemia, in 1 patient each. Of the 75 patients included in this study, 60 were evaluable for response. One patient achieved a complete response for 91 weeks and 6 patients exhibited a partial response (median duration of 23 weeks) with an overall response rate of 11.7%. Disease stabilization occurred in 37 patients (61.7%). Thus, disease control was achieved in 44 of the 60 patientrs (73%). At a median follow‑up period of 53.5 weeks (range, 8.5‑192 weeks), an intention‑to‑treat analysis demonstrated a median time‑to‑disease progression of 25.7 weeks, with a median overall survival of 54.8 weeks. In conclusion, sorafenib was found to be tolerable and effective as first‑line therapy in patients with advanced RCC.

View Figures

View References

1	Karumanchi SA, Merchan J and Sukhatme VP: Renal cancer: Molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens. 11:37–42. 2002. View Article : Google Scholar : PubMed/NCBI
2	Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N and Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 345:1655–1659. 2001. View Article : Google Scholar : PubMed/NCBI
3	Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI and Heng DY: The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 185:60–66. 2011. View Article : Google Scholar : PubMed/NCBI
4	Awada A, Hendlisz A, Gil T, et al: Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer. 92:1855–1861. 2005. View Article : Google Scholar : PubMed/NCBI
5	Clark JW, Eder JP, Ryan D, Lathia C and Lenz HJ: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 11:5472–5480. 2005. View Article : Google Scholar : PubMed/NCBI
6	Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C and Schwartz B: Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Onco. 16:1688–1694. 2005. View Article : Google Scholar
7	Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 23:965–972. 2005. View Article : Google Scholar : PubMed/NCBI
8	Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
9	Escudier B, Eisen T, Stadler WM, et al: TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
10	Eisen T, Bukowski RM, Staehler M, Szczylik C, Oudard S, Stadler WM, Schwartz B, Simantov R, Shan M and Escudier B: The Sorafenib TARGETs Clinical Trial Group: Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol. 24(Suppl 18): 45242006.
11	Bukowski RM, Eisen T, Szczylik C, Stadler WM, Simantov R, Shan M, Elting J, Pena C and Escudier B: Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 25(Suppl 18): 50232007.
12	Di Lorenzo G, Cartenì G, Autorino R, et al: Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 27:4469–4474. 2009. View Article : Google Scholar : PubMed/NCBI
13	Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, Dreicer R, Bukowski RM and Rini BI: Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 116:5383–5390. 2010. View Article : Google Scholar : PubMed/NCBI
14	Escudier B, Szczylik C, Hutson TE, et al: Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 27:1280–1289. 2009. View Article : Google Scholar : PubMed/NCBI
15	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
16	Park SJ, Lee JL, Park I, et al: Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Chemotherapy. 58:468–474. 2012. View Article : Google Scholar : PubMed/NCBI
17	Procopio G, Derosa L, Gernone A, et al: Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncol. 10:1741–1750. 2014. View Article : Google Scholar : PubMed/NCBI
18	Iacovelli R, Cartenì G, Sternberg CN, et al: Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. Eur J Cancer. 49:2134–2142. 2013. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles